lilly cease and desist tirzepatide We saw this coming from a mile away. “Lilly has already sued more than two dozen medical spas, wellness centers compounding pharmacies for selling products claiming to contain tirzepatide. The new Lilly Sends Cease and Desist

Figure 3 3.5 Transcriptomic profiling and identification of DEGs RNA-Seq was conducted to assess mRNA expression profiles in BAT and to investigate transcriptional alterations across the four groups

Presented for research literature review only Gabery S et al

It is also sometimes used off-label to support weight management goals, although it is not FDA approved for this purpose

Oral GLP-1/GIP Agonist (Future) VK2735 The VENTURE-Oral trial demonstrated 12.2% weight loss at 13 weeks with an oral dual agonist formulation, potentially offering a more convenient oral option than Rybelsus if approved

GLP-1s may be appropriate even at lower weights, but only when they align with your broader health goals